Cystinosis: a review by Ibrahim, Mohamed et al.
REVIEW Open Access
Cystinosis: a review
Mohamed A. Elmonem1,2, Koenraad R. Veys1, Neveen A. Soliman3,4, Maria van Dyck1,
Lambertus P. van den Heuvel1,5 and Elena Levtchenko1*
Abstract
Cystinosis is the most common hereditary cause of renal Fanconi syndrome in children. It is an autosomal recessive
lysosomal storage disorder caused by mutations in the CTNS gene encoding for the carrier protein cystinosin,
transporting cystine out of the lysosomal compartment. Defective cystinosin function leads to intra-lysosomal
cystine accumulation in all body cells and organs. The kidneys are initially affected during the first year of life
through proximal tubular damage followed by progressive glomerular damage and end stage renal failure during
mid-childhood if not treated. Other affected organs include eyes, thyroid, pancreas, gonads, muscles and CNS.
Leucocyte cystine assay is the cornerstone for both diagnosis and therapeutic monitoring of the disease. Several
lines of treatment are available for cystinosis including the cystine depleting agent cysteamine, renal replacement
therapy, hormonal therapy and others; however, no curative treatment is yet available. In the current review we will
discuss the most important clinical features of the disease, advantages and disadvantages of the current diagnostic
and therapeutic options and the main topics of future research in cystinosis.
Background
Cystinosis was first described in literature in 1903 by the
Swiss biochemist Emil Abderhalden (1877–1950) as the
familial cystine accumulation disease [1]. Abderhalden
referred to a child initially encountered by Eduard Kauf-
mann, Basel, Switzerland (1860–1931). This patient died
at the age of 21 months with massive cystine accumula-
tion in multiple organs that were discovered at the post-
mortem examination. The Dutch pathologist George
Lignac (1891–1954) was the first to provide a clear sys-
tematic description of the disease in 1924, and the first
to associate cystinosis with its major clinical manifesta-
tions such as rickets, renal disease and growth retardation
[2]. This is why cystinosis was initially termed as the
Abderhalden-Kaufmann-Lignac syndrome. Guido Fanconi
(1892–1979), the Swiss pediatrician, also substantially
contributed to the understanding of cystinosis by explain-
ing the urinary substance losing nature of the disease [3].
Hence, cystinosis was also recognized in the literature as
the Lignac-Fanconi syndrome.
The currently used term “cystinosis” is a modification
from the German term “Cystindiathese” or “hereditary cyst-
ine disease” which was initially used by Emil Abderhalden
to describe the disease in 1903 and was modified in the
English literature to “cystine disease” then “cystinosis”.
Cystinosis (ORPHA213) is a rare autosomal recessive lyso-
somal storage disorder in which the amino acid cystine
accumulates in the lysosomes of cells [4]. Cystinosis is one
of the few rare diseases having a specific treatment. The
aminothiol cysteamine, used for the treatment of cystinosis
for over 20 years now [5], can deplete the intralysosomal
cystine through the reduction of cystine, and the formation
of cysteine and a cysteamine-cysteine mixed disulfide which
exits the lysosome via the cationic amino acid transporter
PQLC2, thus bypassing the original genetic and biochem-
ical defects of the disease [6, 7].
Cystinosis is a systemic disease and cystine crystals, the
pathologic landmark, accumulate in all body cells and tis-
sues. Although cystinosis is a monogenic disease, it has
three major clinical presentations depending on the sever-
ity of mutations affecting the CTNS gene: the infantile
nephropathic form (MIM: 219800, ORPHA411629), the
juvenile nephropathic form (MIM: 219900, ORPHA
411634) and the ocular non-nephropathic form (MIM:
219750, ORPHA411641) [8].
In the current review, we describe the clinical
spectrum of the disease, the diagnostic and management
protocols and the anticipated advances in the near
future.
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Epidemiology
Nationwide birth prevalence data concerning cystinosis are
only reported in few populations. The overall incidence
rates reported in France [9], Australia [10], Germany [11],
Denmark [12] and Sweden [13] were 1:167,000, 1: 192,000,
1: 179,000, 1:115,000 and 1:260,000 live births, respectively.
Higher incidence rate is observed in selected populations
with detected founder mutations as in the province of
Brittany, France (1:26,000 live births) [14] or in the
Saguenay-Lac-St-Jean, Quebec, Canada (1:62,500 live
births) [15]. The highest birth frequency rate ever re-
ported was in the Pakistani ethnic group living in the
West Midlands, UK (1: 3,600) [16]. Since cystinosis is
an autosomal recessive disease, its incidence is expected
to be affected by the extent of consanguinity in the com-
munity. Accurate statistical data about the incidence of
cystinosis in regions with high consanguinity such as
Middle East and North Africa are still lacking; however,
cystinosis was fairly commonly detected among a
large cohort of different lysosomal storage disorders
diagnosed over a six year period in Egypt (29/211 pa-
tients (13.7 %)) [17].
Etiology
Cystinosis is caused by bi-allelic mutations in the CTNS
gene (17p13.2) encoding cystinosin, which is a lysosomal
cystine-proton co-transporter. Consequently, cystine ac-
cumulates in the lysosomes of affected cells and forms
crystals in low lysosomal pH [4].
So far, over 100 pathogenic mutations have been re-
ported in the literature (Fig. 1). The most commonly
detected pathogenic mutation is the 57-kb deletion
present in almost 50 % of CTNS mutant alleles of pa-
tients of North European and North American origin
[18, 19]; however, outside this geographical distribu-
tion, the mutation is almost completely absent, espe-
cially in the Middle East [20]. Severe or truncating
mutations on both alleles are usually associated with
the infantile severe form of the disease, while juvenile
and ocular forms of cystinosis are usually associated
Fig. 1 Schematic representation of the CTNS gene and all reported mutations in cystinosis patients. Exonic mutations are displayed in the lower
half of the figure, while promoter and intronic mutations and large deletions are displayed in the upper half. INC: infantile nephropathic
cystinosis, JNC: juvenile nephropathic cystinosis, OC: ocular cystinosis
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with at least one mild mutation. Genotypic-phenotypic
correlations for the discovered CTNS mutations are sum-
marized in Fig. 1.
Clinical description and complications
Renal manifestations
Three clinical forms of cystinosis can be distinguished,
depending on the age of presentation and the degree of
renal disease severity.
The infantile nephropathic form is the most frequent
(95 %) and the most severe type of cystinosis. The renal
phenotype consists of renal Fanconi syndrome, and a con-
secutively progressive loss of glomerular function leading
to end-stage renal failure [4, 21, 22]. Asymptomatic amino-
aciduria is the first manifestation of renal Fanconi syn-
drome in humans [23, 24] with urinary losses of amino
acids being 6 to 16 times increased compared to the nor-
mal amount [25]. The earlier loss of expression of apical
proximal tubular receptors megalin/cubilin and SGLT-2,
and NaPi-IIa transporters preceding cell atrophy in a
mouse model of cystinosis, provides an explanation for the
early proteinuria, glucosuria, and phosphaturia [26, 27].
By the age of 6 to 12 months, selective proximal tubu-
lar dysfunction develops into the full-blown renal Fan-
coni syndrome, characterized by excessive urinary loss of
amino acids, sodium, potassium, bicarbonate, magne-
sium, carnitine, calcium, phosphate, glucose and low
molecular (LMW) to intermediate molecular weight
(IMW) proteins [23, 25]. Infants present with failure to
thrive, polyuria, polydipsia, episodes of severe dehydra-
tion and electrolyte imbalance, vomiting, constipation
and sometimes vitamin D resistant rickets. Laboratory
findings may include hypokalemia, metabolic acidosis,
hypophosphatemia, hypocalcemia, low carnitine levels
and less frequently hyponatremia. However, metabolic
alkalosis in case of a Bartter-like presentation has also
been reported [28, 29].
At birth, patients show a normal birth length and
weight parameters. By the age of 6 to 12 months, height
drops to the third percentile, and further growth is re-
stricted to less than 60 % of the normal range [8, 30, 31].
Figure 2 represents the typical growth pattern of cystino-
sis patients if specific treatment is not started in the first
year of life. Calciuria and phosphaturia, in combination
with phosphate, calcium, vitamin D and alkalinizing
agent supplementation can cause medullary nephrocalci-
nosis and nephrolithiasis in a subset of patients [32].
Phosphaturia, increased urinary losses of vitamin D
binding protein and decreased renal vitamin D conver-
sion due to decreased activity of alpha-1 hydroxylase in
renal proximal tubules, can lead to vitamin D resistant
hypophosphatemic rickets in children (Fig. 3) and os-
teomalacia in adults [33]. Proteinuria is variable, and
consists initially of low molecular weight proteins (beta-
2-microglobulin, alfa-1-microglobulin, retinol-binding
protein) and intermediate weight proteins (albumin,
transferrin, vitamin D binding protein). Glomerular pro-
teinuria is present starting from early ages and is charac-
terized by excessive urinary losses of albumin and HMW
proteins, and may occur up to nephrotic range [34].
Generally, serum creatinine levels remain within normal
limits until the age of 5 years and only rarely exceed
1 mg/dl below this age [8, 35]. If left untreated or if
treatment started late or even if the patient was not
Fig. 2 Typical growth charts in 2 cystinosis patients: a- Normal growth pattern at birth, followed by decreased growth velocity after six months.
b- Progressive decrease in growth velocity in a patient who started cysteamine therapy after 2 years of age and was not treated with GH. Green
and blue lines represent the 3rd and the 97th percentiles for Height and weight, respectively. (Adapted with permission from Besouw and
Levtchenko, 2010) [27]
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compliant to treatment, end stage renal disease (ESRD)
develops by the end of the first decade of life [36, 37].
Due to the severe polyuria, episodes of dehydration can
be detrimental and usually accelerate the onset of ESRD
at young age.
A small group of cystinosis patients (5 %) is diagnosed
during late childhood or adolescence with the juvenile
(late onset) form of cystinosis [38]. Patients present with
a variable spectrum of features, ranging from isolated
asymptomatic proteinuria, a mild renal Fanconi syn-
drome, to an overt nephrotic syndrome and usually they
do not develop remarkable growth retardation. Gener-
ally, there is a slower progression rate to ESRD and
extra-renal complications. In small series, four out of 14
patients with juvenile cystinosis developed ESRD at 12,
21, 27 and 28 years of age [38].
The adult, non-nephropathic ocular form of cystinosis
is characterized only by photophobia due to corneal
cystine accumulation, and rarely presents before adult-
hood [39]. The kidneys and other organs are spared
from symptoms. In one family the co-existence of ocular
and late-onset forms of cystinosis has been reported,
implying the need of regular renal function controls in
patients with ocular cystinosis [38].
Extra-renal manifestations
Being a systemic lysosomal storage disorder cystinosis
manifests in almost all tissues and organs, and, although
most systemic features are manifested relatively late
during the course of the disease, the pathological pro-
cesses behind these manifestations, especially cystine
accumulation, usually start early. Nearly all nephropathic
cystinosis patients who did not receive early cystine-
depleting therapy or those who are not compliant, will
develop major extra-renal symptoms including retinal,
endocrinological and neuromuscular complications by
the age of 30 years [40].
Corneal cystine accumulation with crystal formation is
the first extra-renal finding affecting all cystinosis pa-
tients [8]. It leads to photophobia and blepharospasm
usually between mid-childhood to early adolescence. [8,
41]. At birth, corneal cystine crystals are not detectable.
They can only be observed from the age of 12 months
through a slit lamp examination by an experienced oph-
thalmologist and are always present by the age of
18 months (Fig. 4). While superficial punctate and fila-
mentary keratopathy is frequently seen in adolescent
and adult patients, band keratopathy, peripheral corneal
neovascularization and posterior synechiae associated
with iris thickening are mostly found in older patients
[42]. Depigmentation of the peripheral retina with pig-
ment epithelial mottling is a commonly encountered
posterior segment complication [43]. It presents mainly
from the second decade of life, but has already been ob-
served as early as at 6 months of age. In 10–15 % of pa-
tients, retinopathy leads to retinal blindness [44].
Progressive cystine accumulation and crystal formation
in thyroid follicular cells causes fibrosis and atrophy
leading to primary hypothyroidism [45, 46], manifesting
in the majority of cystinosis patients (50–70 %) from the
second decade of life [30]. Earlier thyroid changes
affecting thyroglobulin synthesis and iodo-thyroglobulin
processing might be responsible for subclinical hypo-
thyroidism with TSH elevation and normal T3 and T4
Fig. 3 Rickets in cystinosis. a- A cystinosis child with evident rachitic bone deformities. b- Active rachitic bone disease in X-Rays
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plasma concentrations, as it has been shown in a mouse
model of cystinosis [47].
Endocrine and exocrine pancreatic insufficiency have
been also reported in cystinotic patients, usually after
renal allograft transplantation [48, 49]. Fifty percent of
infantile cystinosis patients by the age of 18 develop slow
progressive loss of insulin secretion and C-peptide
production leading to glucose intolerance and diabetes
mellitus [50]. Hepatomegaly and/or splenomegaly are
present in about one third of patients by the age of
15 years, however, liver function usually remains un-
affected [48].
In male cystinosis patients, primary hypogonadism is a
frequent finding (70 %) [51–53]. Recently, Besouw et al.
have shown that although azoospermia was present in
all studied male cystinosis patients under cysteamine
therapy, spermatogenesis was documented on a testicu-
lar biopsy specimen in one renal transplant patient [54].
In females, although delayed puberty is sometimes ob-
served, normal pubertal development is also possible
and in contrast to males, cystinotic females are usually
fertile [55].
Central nervous system involvement is evident in a sub-
group of cystinotic patients and becomes more frequent
with advancing age. Neurological findings include hypo-
tonia, tremor, speech delay, gross and fine motor impair-
ment, idiopathic intracranial hypertension, neurocognitive
dysfunction, behavioral problems and encephalopathy
[56–61]. Despite normal IQ scores, cystinosis patients
have significantly poorer performance in visual spatial and
visual memory skills than normal individuals and, interest-
ingly, their highest scores are in the area of auditory short-
term memory, which could be a compensatory mechan-
ism for their poor visual memory [58, 62]. A recent study
in cystinosis patients aged 3–7 years, using the MRI based
technique, diffusion tensor imaging (DTI) detected the
early selective white matter microstructural changes in the
form of bilaterally decreased fractional anisotrophy and
increased mean diffusivity in the inferior and superior par-
ietal lobules in children with cystinosis corresponding to
the areas of the dorsal and ventral visual pathways [63],
thus giving the pathological explanation for the early onset
of poor visual spatial and visual memory skills. Other
common pathological findings usually observed at older
age include cerebral cortical atrophy, non-absorptive
hydrocephalus, demyelination, and vacuolar, necrotic and
spongiform changes [57, 58].
A distal vacuolar myopathy presenting as progressive
distal muscle wasting and weakness, has been observed
in about 24 % of renal transplant cystinosis patients
[64, 65]. Myopathy generally affects patients from their
second decade of life. Myopathy changes on EMG can be
present in asymptomatic patients, suggesting that clinic-
ally overt muscle weakness might be a late sign of cystino-
tic myopathy [60]. In post-transplant cystinotic patients
who did not receive long-term cystine-depleting therapy,
cystinotic myopathy may cause an extraparenchymal pat-
tern of restrictive lung disease [66]. Swallowing dysfunc-
tion occurs in more than half of patients with myopathy
and its severity also positively correlates with the number
of years without cysteamine therapy [67]. As a result,
aspiration pneumonia constitutes a severe and potentially
lethal complication.
Other observed features related to skin, hair and
salivary glands have also been reported such as congeni-
tal hypopigmentation, premature skin ageing, impaired
sweating and salivation and progressive coarse facial fea-
tures due to subcutaneous cystine infiltration [68]. Ac-
cording to our experience, not only European patients,
but also some patients from other ethnic backgrounds
can present with characteristic blond hair and white
skin. Recently, cystinosin was implicated in the regula-
tion of melanin synthesis as CTNS silencing in a melan-
oma cell model led to over 50 % reduction in pigment
production [69].
Differential diagnosis
Although cystinosis is the most common identifiable
cause of the inherited renal Fanconi syndrome in children,
other metabolic diseases (tyrosinemia, galactosemia, gly-
cogen storage diseases), Wilson’s disease, Dent’s disease
Fig. 4 Corneal cystine crystals. Slit lamp examination of corneal
cystine deposits (courtesy of Prof. Dr. Akmal Rizk, Dr. Mohamed
Gamal and Prof. Dr. Neveen Soliman)
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and Lowe’s syndrome should also be considered in the dif-
ferential diagnosis of the renal Fanconi syndrome. Some
cystinosis patients had atypical presentations and were
initially diagnosed as Bartter’s syndrome or nephrogenic
diabetes insipidus [28, 29]. Most frequent genetic and ac-
quired conditions for the differential diagnosis of cystinosis
are summarized in Table 1.
Cystinosis is also responsible for some cases of child-
hood renal failure, and should be considered in every
young patient presenting with renal failure of unknown
origin [37].
Diagnostic methods
Due to the availability of specific cysteamine therapy, early
diagnosis and management of cystinosis have a great im-
pact on the clinical outcome of patients. There are three
main diagnostic modalities for cystinosis. The current gold
standard is the detection of elevated cystine levels in white
blood cells (WBCs), being extremely sensitive and precise
for the disease. Molecular testing of the relatively small
CTNS gene (12 exons but only 10 are coding) is also a
well- established technique revealing 95 % of disease caus-
ing mutations. The third clinically used confirmatory op-
tion is the detection of the characteristic corneal cystine
crystals by slit lamp examination [27].
Oshima et al. established a highly sensitive and specific
method for cystine measurement in WBCs in 1974 [70].
Their assay was based on the selective binding between
cystine in the WBC sample and cystine binding protein
(CBP) isolated from Escherichia coli in the presence of a
competitor external [14C] cystine, with the resultant
bound radioactivity being inversely proportional to cyst-
ine concentration in the unknown sample. Although still
used in few laboratories, this method is widely replaced
now by high performance liquid chromatography
(HPLC) or liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) methods [71, 72]. Newly diag-
nosed cystinotic patients have WBC cystine levels in the
range of 3–20 nmol half-cystine/mg protein, while con-
trol individuals and heterozygous carriers have levels
<0.2 and <1.0 nmol half-cystine/mg protein, respectively.
The main source of the assay variability lies in the
method applied for WBCs separation, and whether it is
a mixed leucocyte or polymorphonuclear leucocyte
population, thus, the type of cells and the separation
method should be highly standardized for each labo-
ratory. Nevertheless, the instrumentations and tech-
niques involved, so far, in cystine measurement are
sophisticated enough to limit its use to few university
hospitals and research centers mainly in the devel-
oped world. This is further complicated by the sample
sensitivity to storage and transportation conditions,
therefore so far most developing nations are still lack-
ing the assay [73].
Being a monogenic disease, molecular diagnosis is
efficient as a confirmatory tool; however, it is usually
more time consuming than cystine measurement. In
about 5 % of patients pathogenic mutations are not
easily discovered by the usual CTNS gene sequencing,
being either deeply intronic, in the promoter region
or not commonly encountered large deletion or dupli-
cation [74].
The visualization of corneal cystine crystals is the main
diagnostic method for cystinosis in developing nations.
Although reliable and relatively cheap, it needs a consid-
erably experienced ophthalmologist to identify and grade
the crystals properly. Cystine crystals also do not appear
in the slit lamp examination until the second year of life
which delays the start of specific therapy in most pa-
tients [75].
Another possible non-invasive evaluator of the cystine
crystal load is the reflectance confocal microscopy
(RCM). Chiaverini et al. have shown that RCM is able to
detect dermal cystine deposition in young patients with
cystinosis [76]. Cystine deposits were visualized as
bright, round, or oval-shaped dermal particles of variable
size. These particles appear to be specific in cystinosis,
as no particles were identified in control subjects. The
nature of the deposits was further confirmed by electron
microscopy showing that the particles corresponded to
crystalline cystine within fibroblasts in the reticular der-
mis [76]. The test is rapid (5 min), painless and tolerable
even in the youngest children.
Because of the availability of cystine-depleting therapy,
the development of a newborn screening method is very
tempting; however, it is not available so far. The evalu-
ation of cystine levels in blood spots would be logical to
consider but many technical difficulties stand in the way
including the much higher sensitive instrumentation
needed to quantify cystine reliably in a minute amount
of sample (the current ideal sample for WBC cystine is
5–10 ml of blood), the difficulty to prevent the spontan-
eous oxidation of cysteine into cystine in stored blood
spots and the interference from serum cystine levels
which are completely not related to the disease [77]. A
recent study has detected the elevation of sedoheptulose
in dried blood spots of patients homozygous for the
57-kb deletion mutation by tandem mass spectrom-
etry [78]. This is the result of the simultaneous deletion
of the CTNS upstream gene (CARKL/SHPK) which en-
codes the enzyme sedoheptulokinase. Nonetheless, cysti-
notic patients not harboring this mutation, or even
heterozygous would have a completely normal blood spot
sedoheptulose levels, making the clinical use of this
method very limited.
Detection of most CTNS mutations is accomplished
by sequencing individual exons and the adjacent splice
sites, while large deletions and insertions could be detected
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Table 1 Differential diagnosis of cystinosis according to the most common presenting manifestations
Presenting
manifestations
Diseases MIM Gene Protein Other characteristic features
at presentation
Proximal renal
tubular acidosis
Tyrosinemia type I 276700 FAH Fumarylacetoacetase Hepatomegaly, mental
retardation
Galactosemia 230400 GALT Galactose-1-phosphate
uridylyltransferase
Lethargy, jaundice, bleeding
disorders, cataract,
intellectual disability
Hereditary fructose
intolerance
229600 ALDOB Aldolase B Seizures, irritability,
poor feeding, lethargy,
liver disease
Wilson disease 277900 ATP7B Copper transporting
P-type ATPase
Liver disease,
neuropsychiatric
manifestations, Kayser-
Fleischer ring in the cornea
Lowe syndrome 309000 OCRL Phosphatidylinositol 4,
5-diphosphate 5-phosphatase
Congenital cataract,
glaucoma, intellectual
disability, hypotonia,
seizures, behavioral problems
Dent’s disease 300009 CLCN5 Chloride Channel Protein
number 5
Low molecular weight
proteinuria, hypercalciuria,
nephrolithiasis,
nephrocalcinosis, progressive
renal failure
Mitochondrial
disorders:
- Leigh syndrome 256000 COX10 Cytochrome C oxidase
assembly protein
Encephalopathy, myopathy,
respiratory istress,
deterioration of cognitive
function
- Gracile syndrome 603358 BCS1L S. cerevisiae bcs1 protein
homolog
Severe lactic acidosis,
hypoglycemia, cholestasis,
iron overload
- HUPRA syndrome 613845 SARS2 Seryl-t-RNA synthetase Hyperuricemia, pulmonary
hypertension, renal failure,
alkalosis
- Mitochondrial
DNA depletion
syndrome 8
612075 RRM2B Ribonucleotide reductase
small subunit 2 like
Neonatal hypotonia, lactic
acidosis, neurologic
deterioration
- Mitochondrial
DNA depletion
syndrome 13
615471 FBXL4 Leucine rich repeat protein 4 Hypotonia, lactic acidois,
microcephaly, congenital
cataract
Heavy metal
toxicity: Lead,
cadmium
———————— ————————— ———————————
———————————
———————————
Anemia, abdominal pain,
encephalopathy,
osteomalacia, neurological
manifestations
Hypophosphatemic
Rickets
Hypophosphatemic
nephrolithiasis/
osteoporosis I
612286 SLC34A1 Sodium-phosphate
cotransporter, member 1
Nephrolithiasis,
osteoporosis, multiple
fractures
Hypophosphatemic
nephrolithiasis/
osteoporosis II
612287 SLC9A3R1 Sodium/hydrogen exchanger
regulatory factor 1
Nephrolithiasis,
osteoporosis, hypocalcemia,
hypoparathyroidism
Autosomal
dominant
hypophosphatemic
rickets
193100 FGF23 Fibroblast growth factor 23 Fatigue, bony pains,
bone deformities
Autosomal recessive
hypophosphatemic
rickets
241520 DMP1 Dentin matrix acidic
phosphoprotein 1
Retarded skeletal growth,
abnormal mineralization
Hereditary
hypophosphatemic
241530 SLC34A3 Sodium-phosphate
cotransporter, member 3
Elevated serum 1,25-
dihydroxy vitamin D levels,
Elmonem et al. Orphanet Journal of Rare Diseases  (2016) 11:47 Page 7 of 17
by other molecular techniques such as allele specific PCR,
multiplex ligation-dependent probe amplification (MLPA)
or fluorescence in-situ hybridization (FISH) [79–81].
Antenatal diagnosis of cystinosis through the detection
of elevated cystine in cells of fetal origin has been avail-
able for many years now [82]. Two main sample types
are used for this purpose, either chorionic villous biopsy
sample (taken at 8–9 weeks of gestation) or cultured am-
niotic cells (14–16 weeks of gestation). Cystine can be
directly quantified in these cells with either HPLC or LC-
MS/MS [83]. DNA analysis for detecting mutant alleles is
currently the most frequently used antenatal screening
method, but to reach a molecular diagnosis in a timely
fashion for an informed decision, knowing the pathogenic
mutation(s) in a previous sibling is highly favored.
Management
Optimal symptomatic treatment of the renal Fanconi
syndrome and extra-renal complications, combined with
cysteamine, the specific cystine-depleting therapy repre-
sent the mainstay of cystinosis treatment [84]. Early
diagnosis is of vital importance to ensure better control
of cystinosis as the early start of specific treatment en-
sures better growth and delays the onset of ESRD and
most of extra renal complications.
Symptomatic treatment
The supportive, symptomatic treatment of cystinosis
aims to (1) maintain an adequate fluid- and electrolyte
substitution and safeguard the acid–base balance, (2)
provide nutritional support, (3) prevent the development
of rickets and (4) ensure adequate substitution of needed
hormones.
Due to their polyuria and impaired sweating ability,
cystinosis patients should have access to water and toi-
lets at all times, and should avoid excessive exposure to
heat and sun in order to maintain proper hydration [27].
Electrolyte substitution is provided through oral solu-
tions of sodium bicarbonate or sodium/potassium cit-
rate. Substitution with sodium or potassium phosphate
and 1–25-(OH)2 cholecalciferol should be initiated from
early childhood to compensate for the phosphate imbal-
ance and to prevent rickets in patients with preserved
GFR. Sodium, potassium, bicarbonate and phosphate
need to be monitored frequently, and the dose of substi-
tution needs to be adjusted accordingly. If phosphate,
1,25-(OH) 2 cholecalciferol and bicarbonate are exces-
sively substituted, nephrocalcinosis may occur [85, 86].
There is no consensus on the systematic use of indometh-
acin in order to enhance sodium reabsorption at the as-
cending limb of the loop of Henle and the collecting ducts
Table 1 Differential diagnosis of cystinosis according to the most common presenting manifestations (Continued)
rickets with
hypercalciuria
hypercalciuria, osteomalacia,
nephrolithiasis,
nephrocalcinosis
Vitamin D
dependent
rickets type I
264700 CYP27B1 25-hydroxyvitamin
D3-1-alpha-hydroxylase
Hypotonia, muscle weakness,
seizures
Vitamin D
dependent
rickets type II
277440 VDR vitamin D receptor Alopecia, hypocalcemia,
secondary
hyperparathyroidism,
osteomalacia, osteitis
fibrosa cystica
Stunted growth Cystic fibrosis 219700 CFTR Cystic fibrosis transmembrane
conductance regulator protein
Frequent chest infections,
pancreatic insufficiency
Chronic
malnutrition
———————— ————————— ———————————
————————————
——————————
Fatigue, anemia, poor
cognitive function,
behavioral changes, history
of poor socioeconomic
standard
Hormonal causes
- Hypothyroidism ———————— ————————— ———————————
———————————
———————————
Lethargy, fatigue, dry skin,
cold intolerance,
constipation, mental
subnormality
- GH deficiency ———————— ————————— ———————————
————————————
——————————
Short stature with general
good health, normal
intelligence
Familial ———————— ————————— ———————————
———————————
———————————
Family history
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[85]; however, this treatment can be useful to decrease
polyuria and reduce electrolyte losses.
Carnitine replacement has been suggested because of
low plasma and muscle carnitine levels in cystinosis pa-
tients, though clinical improvement with this therapy
has not been proven yet [87, 88]. The majority of cysti-
nosis patients experience a progressive failure to thrive
for which a high-caloric diet is recommended in associ-
ation with other lines of treatment [89]. Feeding by
nasogastric tube should be considered early, especially in
children with anorexia, complaints of anorexia and fre-
quent vomiting, or to facilitate administration of medical
treatment.
Because of the multiple endocrinopathies caused by
cystinosis, hormone replacement therapy plays an im-
portant role in symptomatic care. Careful monitoring of
the thyroid, and later pancreatic function during child-
hood and adolescence, is important. In the absence of
poor cystine-depleting therapy and renal insufficiency,
growth hormone replacement therapy can be considered
to prevent growth retardation despite a normal growth
hormone axis [90]; however, the long term implications
of growth hormone replacement in patients with cysti-
nosis is unclear. Currently, insufficient data is available
on the pathophysiology of the azoospermia observed in
male cystinosis patients. Testosterone supplementation
is indicated in patients with a primary testicular failure
and low plasma testosterone levels [54].
Angiotensin converting enzyme inhibitors (ACE inhibi-
tors) are a well-established treatment to reduce protein-
uria of glomerular origin and to slow down the decline of
glomerular filtration rate in chronic renal failure. Greco et
al. reported over 20 years of follow up in cystinosis
patients, during which the use of ACE inhibitors was asso-
ciated with slower deterioration of renal function [91];
however, because of the risk of hypotension and conse-
quent renal function decline, ACE inhibitors must be used
with caution in patients with extracellular volume and so-
dium depletion [92]. The combined use of ACE inhibitors
together with indomethacin should be strictly avoided.
In case of renal failure, renal transplantation is the
treatment of choice. As renal disease does not recur in
the transplanted kidney, kidney graft cures the ESRD,
but has no effect on the multi-systemic complications.
Therefore, cystine-depleting therapy has to be taken life-
long. Although cystine crystals have been observed in
the renal graft, they are of no pathological nor clinical
significance since they arise from the host mononuclear
cells [93]. In comparison to other renal diseases, renal
graft survival in cystinotic patients has been reported as
superior, although this has not been demonstrated in
ERA-EDTA registries [94–97].
Since fluid and electrolyte losses generally decrease
during renal replacement therapy, nephrectomy of the
native kidneys is rarely needed. As other post-transplant
patients, all cystinosis patients should be monitored for
immunodeficiency and infections related to immunosup-
pressive agents after renal transplantation.
Cystine-depleting therapy
The aminothiol cysteamine (beta-mercaptoethylamine)
is currently the only target-specific treatment for cysti-
nosis patients. It aims to deplete lysosomal cystine in all
body cells and tissues. The most commonly used cyste-
amine preparation is the immediate-release cysteamine bi-
tartrate (IR-CYS) (Cystagon®, Mylan Pharma, Morgantown,
WV, USA and Orphan Europe, Paris, France). The drug
has been approved for clinical use in cystinosis in 1994 in
the USA, and in 1997 in Europe [98].
Cysteamine improves overall prognosis by delaying the
progression to end-stage renal disease by 6 to 10 years,
and thus the need for renal transplantation during child-
hood [8, 30, 85, 99–103]. Cysteamine has also been
shown to prevent or postpone the development of some
extra-renal complications. It reduces the need for thy-
roid hormone replacement therapy, depletes the muscle
parenchyma of cystine hereby reducing myopathy, delays
pulmonary and pancreatic dysfunction and prevents
growth failure when initiated in early infancy [30, 99–101].
In a large cohort of adult cystinotic patients, the frequency
of diabetes and myopathy decreased from 28 % to 0 % and
from 60 % to 0 %, respectively when the duration of cyste-
amine treatment exceeded 20 years, while the percentage
of hypothyroidism decreased from 87 % to 56 % in patients
having cysteamine for more than 8 years [100].
Cysteamine has been shown to prevent growth retard-
ation if initiated in early infancy [31, 97, 104]. However, it
is unable to induce a catch-up growth when growth
retardation has already set in [90, 91]. Figure 5 demon-
strates the importance of early cysteamine therapy to pre-
vent growth retardation. Therefore, cysteamine treatment
should be started as soon as possible, and needs to be
continued lifelong. In general, the effect of cysteamine in
infantile cystinosis is at its best when treatment is initiated
in the first year of life, compliance was maintained and
leucocyte cystine levels were kept below 1 nmol ½ cystine/
mg protein [36]. However, Oral cysteamine has no effect
on the renal Fanconi syndrome, male infertility or corneal
cystine accumulation [8]. Topical cysteamine therapy
can be used to dissolve the corneal cystine crystals,
thus treating the photophobia. Cysteamine eye drops
are recommended to be used frequently (>10 times
per day), but due to acidic formulation are frequently
associated with a burning sensation that is especially an-
noying for children, hampering the compliance. An oph-
thalmic gel formulation has been recently developed
(Cystadrops®, Orphan Europe, Paris, France) and proven
to be effective when administered 4 times a day (0.55 %,
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one drop in each eye per dose) [105]. Ocular symptoms
have shown to improve in a couple of weeks, and corneas
become clear within few months.
The leucocyte cystine level is today the only available
biomarker for monitoring the effectiveness of oral
cystine-depleting therapy. The tissue cystine levels at
which progressive renal failure and extra-renal complica-
tions can be prevented, are unknown. Hence, the 90th
percentile of cystine levels in polymorphonuclear cells
(<1 nmol ½ cystine per mg protein), seen in heterozy-
gotes, is used as the upper cystine limit. The leucocyte
cystine content returns to its initial levels about 6 h after
the last administration, therefore the immediate release
formulation of cysteamine bitartrate (IR-CYS) has to be
taken at a 6-h interval. Greater compliance with oral
cysteamine therapy yields greater preservation of renal
glomerular function as for every year of excellent cystine
depletion, nearly one year of renal function was pre-
served [106].
Cysteamine is a potent gastric acid-secretagogue and
has been used to induce duodenal ulceration in laboratory
animals [85]. In children, a fourfold increase in gastric acid
production and 50 % increase in serum gastrin levels
in comparison to baseline levels, have been reported
[107, 108]. Hence, gastrointestinal complaints as nausea,
dyspepsia, vomiting and epigastric pain are frequent and
cause cysteamine intolerance in approximately 14 % of pa-
tients [30, 99, 109]. In our experience, these complaints
can be minimized by the low start and gradual increase in
cysteamine dosage. Use of proton pump inhibitors has
been found effective in the management of gastric acid hy-
persecretion and ulcerogenicity [110]. In selected patients,
a Nissen fundoplication may be of help. A small amount
of cysteamine is also metabolized into sulfur-containing
compounds (dimethylsulfide, methanethiol), which cause
halitosis and a bad sweat odor. For this, oral supplements
of riboflavin and chlorophyll tablets are used by some pa-
tients [84, 111].
It has been suggested to calculate the cysteamine dose
based on body surface area (1.30 g/m2/day; maximum of
1.95 g/m2/day) instead of body weight (50 mg/kg/day),
to avoid overdosing [112]. Recently, some patients
treated with high cysteamine doses (>1.95 g/m2/day)
were reported to have skin striae, bone pain, myalgia,
and endothelial proliferative lesions on the elbows showing
reactive angioendotheliomatosis on skin biopsy. These ad-
verse events developed in a small proportion of patients,
and, while bone and joint pain remained in some patients,
cutaneous manifestations resolved after lowering the dose
of cysteamine [113].
Other reported adverse effects of cysteamine include
hyperthermia, lethargy, neutropenia, seizures and aller-
gic rash [114]. Fortunately, these effects are reversible,
and when cysteamine is started at a low dose and in-
creased gradually, these complaints can be prevented
[114]. Based on the observation of dose-related (100–
150 mg/kg/day) development of a cleft palate, kyphosis,
intrauterine growth retardation and intrauterine death
with cysteamine treatment in the rat, it is recommended
to discontinue cysteamine in women planning pregnancy
[115, 116]. The potential risks of cysteamine discontinu-
ation for several months should be carefully balanced
against the desire to have children.
Taken together, current cysteamine therapy with its
strict dosing regimen and significant adverse effects, im-
poses a significant burden on cystinosis patients. It has
been estimated that only one third of patients are
able to adhere to the strict dosing schedule [102].
Poor compliance leads to a less favorable prognosis
with progressive renal function deterioration and poor
growth [109].
Recently, a new twice-daily delayed-release enteric-
coated formula of cysteamine bitartrate (DR-CYS) (Pro-
cysbi™, Raptor Pharmaceuticals Inc., Novato, CA, USA)
has been approved for clinical use by the US Food and
Fig. 5 The effect of cysteamine treatment in two siblings with
nephropathic cystinosis. The growth in the 30-months old younger
sibling (right side, 86 cm, 11.5 kg) who received pre-symptomatic
cysteamine therapy at 3 months of age exceeded that of his
56-months old elder brother (left side, 80 cm, 10.5 kg) with later
diagnosis and treatment at the age of 20 months (courtesy of
Dr. Rasha Helmy and Prof. Dr. Neveen Soliman)
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Drug Administration (FDA) and European Medicines
Agency (EMA) in 2013 for the treatment of cystinosis. It
was developed based on the observation that direct ad-
ministration of cysteamine in the small intestine resulted
in higher plasma concentrations and a higher area under
the curve in comparison to administration in the stom-
ach or colon [117]. It has been hypothesized that the
greater surface area and the improved absorption rate
from the small intestine, and less first pass metabolism,
can explain this finding [118]. This new formulation
consists of an enteric-coated capsule, containing micro-
spheronized beads. It only needs to be administered
twice daily, instead of four times daily. DR-CYS has the
potential to improve compliance through its better dos-
ing regimen. Table 2 provides the most important guide-
lines for the management of cystinosis [84].
Therapeutic monitoring
The current gold standard in the therapeutic monitoring
of cystinotic patients is the WBC cystine assay. Theoretic-
ally, a more specific and ideal therapeutic monitor would
be the direct assessment of the fluctuating lysosomal cyst-
ine load in different tissues in response to treatment; how-
ever, the invasiveness of tissue samples is prohibitive,
especially in children. WBCs offer the second best option,
and since cystine accumulates preferentially in poly-
morphonuclear leucocytes but not in lymphocytes,
granulocyte separation is preferred to a mixed leucocyte
population [119]; however, the large blood volume needed,
the analyte instability during transportation, the difficult
technique and the unavailability of the assay in many
countries, all make the WBC cystine assay far from being
perfect as a therapeutic monitor. Furthermore, the ex-
tremely short life span of polymorphonuclear leucocytes
(≈12 h) might not be ideal for the long term follow-up in
patients with unstable compliance [77].
Recently, several non-invasive immunological markers
have been proposed to assess the disease activity upon
diagnosis and during follow up of cysteamine treatment.
The immune system is expected to play a major role in
the pathogenesis of nephropathic cystinosis and its rapid
progression to ESRD unlike other types of hereditary
Fanconi syndromes. Prencipe et al. detected the stimula-
tion of the inflammasome related cytokines: IL-1β, IL-6
and IL-18 in human peripheral mononuclear cells when
exposed to cystine crystals, in the plasma of cystinotic
patients and in the serum and tissues of Ctns knocked-
out mice [120]. On the other hand, we reported the sig-
nificant elevation of the macrophage marker chitotriosi-
dase in cystinotic patients. Moreover, control human
macrophages were potently activated in vitro when ex-
posed to different concentrations of cystine crystals
through the significant elevations of TNF-α and chitotrio-
sidase in both supernatant and cell lysate. Chitotriosidase
activities were also significantly elevated in the plasma of
cystinotic knocked-out versus wild-type mice [73]. These
immune based markers could be promising indirect indi-
cators of the disease severity and hence the response to
treatment, as the cystine crystal accumulation in cystinosis
is the main motive behind their release. Besides, they are
much more stable and less technically demanding than
the WBC cystine assay. Another possible therapeutic
monitor of the cystine crystal load needing further evalu-
ation is the in vivo reflectance confocal microscopy of the
skin [76].
Prognosis
Since it was first reported in early twentieth century,
prognosis of cystinosis has improved dramatically, par-
ticularly with the advent of cystine-depleting treatment
and renal replacement therapy (dialysis and kidney
transplantation) in the early 1980s. Consequently more
patients are increasingly growing into adulthood instead
of succumbing to ESRD by late 1st or early 2nd decade
of life. With the increased life expectancy more long-
term complications are being recognized and reported,
that did not have enough time to evolve in the pediatric
age group [100].
North American Pediatric Renal Transplant Cooperative
Study suggests that the outcome of renal transplantation
is favorable in patients with a primary diagnosis of cysti-
nosis [94]. A large European observational registry study
reported a significant delay in the age of initiation of renal
replacement therapy in nephropathic cystinosis patients
(0.15 year per calendar year, 95 % confidence interval:
0.1–0.21 year) which wasn’t observable in a matched co-
hort of non-cystinotic pediatric patients who started renal
replacement therapy in the past 2 decades [101]. In an
adult patient cohort, renal transplant recipients with cysti-
nosis had a better long-term outcome than other renal
transplant recipients. Authors confirmed, by multivariate
analysis, that cystinosis is an independent protective factor
for graft survival [96].
Nowadays cystinosis is increasingly being diagnosed at
younger age allowing early and adequate initiation of
cystine-depleting therapy which significantly prevents, or
at least delays, the complications of the disease. That
being said, adherence to therapy is critical to improved
clinical outcomes. In patients with poor compliance to
frequent dosing formulation, the administration of the
newly developed delayed-release formulation is likely to
improve patient compliance resulting in fewer long-term
complications of cystinosis and improved quality of life.
Even though cystinosis does not recur in the graft after
renal transplantation, yet it continues to progress in
other organs and tissues causing complications that may
worsen the prognosis, hence the need to continue cyste-
amine therapy even after kidney transplantation.
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Table 2 Treatment guidelines for cystinosis
Medication Daily dose Frequency Remarks
Symptomatic treatment
Renal Fanconi syndrome
Polyuria Free water supply Day and night Special attention for sufficient hydration in
case of fever, diarrhea and external heat
Early tube feeding may be needed for water
requirements
Malnutrition high caloric intake 130 % of RDI Tube feeding can be needed in young infants
Renal salt loosing sodium citrate or sodium
bicarbonate
Oral 2–10 mmol/kg QID Between meals
Alkali losses citrate or bicarbonate as
sodium & potassium salts
Oral 5–15 mmol/kg QID Normal bicarbonate level (21–24 mmol/l)
should be achieveda
Potassium losses potassium citrate or potassium
chloride
Oral 2–10 mmol/kg QID Potassium level > 3 mmol/l should be
achieveda
Phosphate losses sodium or potassium
phosphate
Oral 30–60 mg elementary
P/kg
QID Normal age-related phosphate levels should
be achieveda
High doses of phosphate supplements can
cause or aggravate nephrocalcinosis
Treatment of rickets calcidiol Oral 10–25 μg QD Follow-up serum calcium concentration to
prevent hypercalcemia
alpha-calcidol or calcitriol Oral 0.04–0.08 μg/kg
Copper deficiency copper supplementation no data is available in
cystinosis
1–10 mg/day depending on age and
serum copper levels
Chlorophyllin tablets that are used to mitigate
halitosis contain 4 mg of elemental copper
per tablet
Difficult to control
electrolyte losses
and polyuria
indomethacin Oral 1–3 mg/kg BID Follow-up serum creatinine
Discontinue in case of dehydration
Concomitant use with ACE inhibitors is
contra-indicated
Carnitine losses L- carnitine Oral 20–50 mg/kg TID Not proven effect on clinically relevant muscle
health
Proteinuria ACE-inhibitors (enalapril) Oral 0.10–0.25 mg/kg
(for enalapril)
QD Control serum creatinine and potassium
administration at night to avoid hypotension
complaints
Concomitant use with Indomethacin is
contra-indicated
Hormonal substitution
Hypothyroidism levothyroxin Oral QD Start by 25 % of the recommended dose
and increase to full dose in 4 weeks
<12 years:5 μg/kg
>12 years: 2–3 μg/kg
Adults: 1.7 μg/kg
Growth retardation rhGH SC 0.05 mg/kg QD Early initiation when growth failure persists
after optimal control of feeding, electrolytes
and rickets
Higher doses of phosphate supplementation
may be needed
Glucose intolerance insulin SC (cfr endocrinology) Control by blood glucose
Regular control of Hb A1C
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Future prospects and unresolved questions
Recent studies linked cystinosin deficiency in cystinosis
to other pathophysiologic mechanisms not related to
cystine accumulation such as altered vesicle trafficking
and impaired mTOR signaling [121–123], thus a better
understanding of the pathogenic mechanisms of cystino-
sis is highly needed to plan and develop more efficient
therapeutic targets. Multiple cell and animal cystinotic
models have been developed to better understand and
characterize the different phenotypic features of the dis-
ease. Immortalized cell lines for cystinotic proximal tubu-
lar epithelial cells and podocytes have been established
and sustained from either biopsy material or exfoliated
cells in urine [122–125]. The mouse model for cystinosis
has been also available for over a decade now [126]. Al-
though, it can accumulate cystine in most organs, many
important phenotypic features like tubulopathy and renal
failure were not expressed in the initial model. A second
mouse model was later developed on a pure C57BL/6
background that avoided some of the pitfalls of the first
one [127]. These cell and animal models provide indis-
pensable tools to study pathologic and molecular mecha-
nisms of the disease. They can be also used to evaluate the
in vitro and in vivo responses to experimental new thera-
peutic drugs and different therapeutic strategies.
With the current rapid advance in the technology of
tandem mass spectrometry, the sensitivity of recent ma-
chines are almost two to three orders of magnitude the
older ones, thus the development of a suitable method
for the newborn screening of cystinosis can be applicable
in the near future. An interesting approach is the quanti-
fication of the deficient protein cystinosin by peptide
Immunoaffinity enriched LC-MS/MS analysis. The
technology has already been applied for the detection
of signature proteins for three primary immuno-
deficiency diseases: severe combined immunodeficiency
(SCID), Wiskott–Aldrich syndrome (WAS), and X-linked
agammaglobulinemia (XLA) [128].
Although, the newly investigated diagnostic markers
look promising for the monitoring of disease activity and
treatment response [73, 76, 120], longitudinal clinical
studies are strongly needed to validate these observa-
tions. Laboratory markers as chitotriosidase and inter-
leukins, while being much easier to sample and measure
than WBC cystine, are not strictly specific for cystinosis,
thus sensitivity and specificity issues need to be handled
carefully before determining their utility as therapeutic
monitors. On the other hand, the monitoring of the in
vivo dermal cystine crystals by confocal microscopy,
while being extremely specific for the disease, needs a
great deal of experience to operate the instrument and
interpret the results. Whether this experience can be
available for routine clinical use or not, only the future
can tell.
The search for therapeutic substitutes for cysteamine
is now strongly ongoing. Adverse effects and compliance
issues are still hindering the full capacity of the drug
even after the development of the longer acting formula-
tion. The therapeutic focus now is not just cystine deple-
tion, but also how to alleviate other possible harmful
pathogenic mechanisms in cystinosis such as inflam-
mation, autophagy and oxidative stress [120, 129, 130].
New promising therapeutics that can target these differ-
ent disease mechanisms are being currently evaluated in
Table 2 Treatment guidelines for cystinosis (Continued)
Cysteamine treatment
Systemic
administration
immediate release cysteamine
bitartrate (Cystagon®)
1.30–1.95 g/m2 QID Start at low dose (1/6 th of optimal dose),
gradual increase over 6–8 weeks
delayed release cysteamine
bitartrate (Procysbi®)
Start with 80 % of the
immediate-release form
BID Gastrointestinal complaints: add proton
pomp inhibitors
Skin lesions (striae, molluscoid tumor at
elbows): dose reduction by 25–50 %,
control for copper deficiency
Regular dosing of WBC cystine levels
(children x4 per year, adults x1-2 per year)b
Corneal cystine crystals cysteamine eye drops 0.5 % topical application 8–10 time daily Yearly eye examination
cysteamine eye gel
(Cystadrops®)
QID
Varia
Gastro-intestinal
complaints
Proton pump inhibitors
omeprazole
<10 kg: 1- mg/kg BID
10–20 kg: 10–20 mg BID
>20 kg: 20–40 mg BID
aTrough levels of electrolytes and phosphate (before the administration of the next dose) should be measured
bBlood for the determination of WBC cystine levels should be taken 6 h after Cystagon® and 12 h after Procysbi® administration
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cell and animal models. Hematopoietic stem cell trans-
plantation in humans is another interesting therapeutic
option, raising new hopes in finding a cure for cystinosis
and further improving long-term clinical outcomes. Being
highly successful in the mice model [131, 132], therapeutic
human trials are currently being planned but whether it is
going to be as successful and safe in humans as in mice, is
yet to be determined.
Conclusions
Cystinosis is a systemic disease that needs a multilevel
clinical collaboration to rapidly diagnose and properly
treat. The current diagnostic and therapeutic regimens
made it possible for the transition of most cystinotic pa-
tients to adulthood; however, the search for more effi-
cient screening and better therapeutic options through
unravelling the basic pathogenic mechanisms of the dis-
ease will surely hold the promise to a better future.
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